Lexaria Bioscience Corp. (NASDAQ: LEXX) Participates in the Benzinga Global Small Cap Conference; Committed to Innovation and Improving Quality of Life
Lexaria presented at this year’s Benzinga Global Small Cap Conference held on December 8-9, 2021 The event came right after the company announced human clinical hypertension study HYPER-H21-4, its most ambitious one yet Lexaria plans to sublicense its patented DehydraTECH(TM) technology worldwide, allowing for more people to benefit from it Going into 2022, the company looks forward to reporting on results from its HYPER-H21-3 clinical study and receiving Independent Review Board (“IRB”) approval for its HYPER-H21-4 study Lexaria Bioscience (NASDAQ: LEXX) just participated in this year’s Benzinga Global Small Cap Conference. The two-day event was a showcase for small cap…